Fate Therapeutics, Inc. Price & Performance (FATE)
Stock Performance
Fate Therapeutics, Inc.
$1.11USD
++$0.06 (+5.71%)
After Hours
+$0.02 (+1.8%)
- $1.08
- $5.92
- -0.6
- $1.02
- $0.66
- 1.69M
- $1.17
- $127.21M
- 0.00%
Open
Year High
P/E Ratio
Low
Year Low
Volume
High
Market Cap
Dividend Yield
What's Happening
Peers
Income Statement
Revenue
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
Revenue | $31M | $56M | $96M | $64M | $14M |
Cost of Revenue | $126M | $5.9M | $14M | $162M | $0 |
Gross Profit | -$94M | $50M | $83M | -$98M | $14M |
Gross Profit % | -300% | 90% | 86% | -155% | 100% |
R&D Expenses | $126M | $216M | $320M | $173M | $135M |
Cash Flow
Net Income
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
Net Income | -$173M | -$212M | -$282M | -$161M | -$186M |
Dep. & Amort. | $3.1M | $5.9M | $14M | $18M | $9.9M |
Def. Tax | $1.7M | $5.1M | $0 | $0 | $0 |
Stock Comp. | $31M | $54M | $79M | $43M | $41M |
Chg. in WC | -$13M | $2.1M | -$35M | $19M | $0 |
Balance Sheet
Cash
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
Cash | $167M | $134M | $61M | $42M | $36M |
ST Investments | $316M | $482M | $375M | $273M | $243M |
Cash & ST Inv. | $483M | $616M | $436M | $315M | $279M |
Receivables | $5.5M | $8.7M | $38M | $1.8M | $3.5M |
Inventory | $1 | $0 | $1 | $0 | $0 |
Related
Financial information provided by Financial Modeling Prep. Options data provided by Unusual Whales. Live transcripts provided by Quartr. All data is provided for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. · See all tickers.